Becton, Dickinson and Company (BDX) Expected to Announce Earnings on Thursday

Becton, Dickinson and Company (NYSE:BDX) is anticipated to release its Q4 2025 results before the market opens on Thursday, November 6th. Analysts expect Becton, Dickinson and Company to post earnings of $3.93 per share and revenue of $5.9120 billion for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earningreport for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:00 AM ET.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company had revenue of $5.32 billion during the quarter. On average, analysts expect Becton, Dickinson and Company to post $14 EPS for the current fiscal year and $16 EPS for the next fiscal year.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $177.20 on Tuesday. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The company has a 50-day moving average of $188.03 and a two-hundred day moving average of $182.77. The stock has a market cap of $50.79 billion, a price-to-earnings ratio of 31.87, a PEG ratio of 1.42 and a beta of 0.25. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62.

Insider Activity at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director owned 22,226 shares of the company’s stock, valued at $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 1,895 shares of company stock valued at $358,995 over the last 90 days. Company insiders own 0.36% of the company’s stock.

Institutional Investors Weigh In On Becton, Dickinson and Company

Several hedge funds and other institutional investors have recently modified their holdings of BDX. Brighton Jones LLC grew its stake in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares during the last quarter. Empowered Funds LLC grew its stake in shares of Becton, Dickinson and Company by 20.4% in the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock worth $1,827,000 after acquiring an additional 1,354 shares during the last quarter. Marshall Wace LLP grew its stake in shares of Becton, Dickinson and Company by 365.1% in the second quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier’s stock worth $5,491,000 after acquiring an additional 25,022 shares during the last quarter. NewEdge Advisors LLC boosted its stake in Becton, Dickinson and Company by 34.7% during the second quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier’s stock worth $4,048,000 after buying an additional 6,058 shares in the last quarter. Finally, Treasurer of the State of North Carolina boosted its stake in Becton, Dickinson and Company by 1.0% during the second quarter. Treasurer of the State of North Carolina now owns 133,625 shares of the medical instruments supplier’s stock worth $23,017,000 after buying an additional 1,283 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on the stock. Piper Sandler reiterated a “neutral” rating and issued a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Argus increased their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Morgan Stanley increased their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and issued a $211.00 price target on shares of Becton, Dickinson and Company in a research report on Thursday, October 16th. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $205.40.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.